No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TNDM240816C47500
- 2.70
- +0.18+7.14%
15min DelayClose Jul 23 16:00 ET
2.70High2.51Low
2.51Open2.52Pre Close3 Volume136 Open Interest47.50Strike Price791.00Turnover88.41%IV14.17%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry2.70Extrinsic Value100Contract SizeAmericanOptions Type0.4171Delta0.0389Gamma16.44Leverage Ratio-0.0836Theta0.0104Rho6.86Eff Leverage0.0443Vega
Intraday
- 5D
- Daily
News
An Insider At Tandem Diabetes Care Lowered Their Holding Recently
Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024
Glaukos Cut as Citi Reviews U.S. MedTechs
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $57
Understanding Tandem Diabetes Care: Joanne Wuensch's Investment Perspective
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
Comments
$Tandem Diabetes Care(TNDM.US$
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
2
Despite losses and negative cash flow, the company's US$178.2m balance sheet allows for at least two years of growth spending. However, the stock is seen as risky due to these financial conditions.
1
Tandem Diabetes Care's share price rise sparks hope, but turnarounds can be risky. The gap between revenue and share price growth could warrant further investigation. Last year's performance suggests unresolved issues, as it underperformed the annualised 10% loss over the past five years.
The stock is undervalued, indicating a potential buy opportunity. The company's positive future outlook and expected earnings increase aren't fully reflected in the current share price. Consider the company's financial health as well.
Despite the good rate of top-line growth at Tandem Diabetes Care, the severe share price drop indicates the company's losses might be larger than expected. Given the stock's past poor performance, there may be unresolved challenges the company is facing.
Read more